{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T21:44:48Z","timestamp":1775598288673,"version":"3.50.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>There are major hurdles to the use of tyrosine kinase inhibitors (TKIs) and any other agents with significant toxicities (which means practically the preponderance of potential effective agents) in the context of prevention\/anti-progression (interception) studies. We will discuss epidermal growth factor receptor (EGFR) inhibitors as examples, both in a primary prevention setting, where agent(s) are administered to individuals with no cancer but who might be considered at higher risk due to a variety of factors, and in anti-progression\/interception studies, where agent(s) are administered to persons with known preinvasive lesions (e.g., colon adenomas, lung nodules, ductal carcinoma <jats:italic>in situ<\/jats:italic> (DCIS), or pancreatic intraepithelial neoplasia (PanIN) lesions in the pancreas) in an attempt to reverse or inhibit progression of these lesions. Multiple potential hurdles will be examined, including: a) toxicity of agents, b) the likely range of subtypes of cancers affected by a given treatment (e.g., EGFR inhibitors against EGFR mutant lung adenocarcinomas), c) the availability of practical endpoints besides the blocking of cancer formation or pharmacokinetics related to the agents administered in a primary prevention study, and d) the interpretation of the regression or blockage of new preinvasive lesions in the anti-progression study. Such an anti-progression approach may help address some of the factors commented on regarding primary prevention (toxicity, potential target organ cancer subtypes) but still leaves major questions regarding interpretation of modulation of preinvasive endpoints when it may not be clear how frequently they progress to clinical cancer. Additionally, we address whether certain recent preclinical findings might be able to reduce the toxicities associated with these agents and perhaps even increase their potential efficacy. Antibodies and TKIs other than the EGFR inhibitors are not discussed because few if any had been tested as monotherapies in humans, making their efficacy harder to predict, and because a number have relatively rare but quite striking toxicities. Furthermore, most of the practical hurdles raised regarding the EGFR inhibitors are relevant to the other TKIs. Finally, we briefly discuss whether early detection employing blood or serum samples may allow identification of high-risk groups more amenable to agents with greater toxicity.<\/jats:p>","DOI":"10.3389\/fcell.2023.1170444","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T08:55:55Z","timestamp":1682326555000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention\/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitations"],"prefix":"10.3389","volume":"11","author":[{"given":"Konstantin H.","family":"Dragnev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christo P. C.","family":"Dragnev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald A.","family":"Lubet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"6677","DOI":"10.3390\/molecules26216677","article-title":"Globally approved EGFR inhibitors: Insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism","volume":"26","author":"Abourehab","year":"2021","journal-title":"Molecules"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9380","DOI":"10.1158\/0008-5472.CAN-07-0710","article-title":"Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer","volume":"67","author":"Buchanan","year":"2007","journal-title":"Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/annonc\/mdm601","article-title":"A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer","volume":"19","author":"Burstein","year":"2008","journal-title":"Ann. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research","year":"2014","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrurol.2014.129","article-title":"Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer","volume":"11","author":"Choi","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1200\/JCO.20.02824","article-title":"Comparison of radiation with or without concurrent trastuzumab for HER2-positive ductal carcinoma in situ resected by lumpectomy: A phase III clinical trial","volume":"39","author":"Cobleigh","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/978-3-642-55647-0_9","article-title":"Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study)","volume":"163","author":"Cuzick","year":"2003","journal-title":"Recent Results Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","article-title":"Use of anastrozole for breast cancer prevention (IBIS-II): Long-term results of a randomised controlled trial","volume":"395","author":"Cuzick","year":"2020","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): An international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/138920211794520132","article-title":"Genetic and epigenetic alterations in pancreatic carcinogenesis","volume":"12","author":"Delpu","year":"2011","journal-title":"Curr. Genomics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.4161\/cc.27201","article-title":"Lapatinib inhibits stem\/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS)","volume":"13","author":"Farnie","year":"2014","journal-title":"Cell Cycle"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study","volume":"90","author":"Fisher","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"B15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S0140-6736(15)01129-0","article-title":"Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial","volume":"387","author":"Forbes","year":"2016","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"Pulsatile\" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e147096","DOI":"10.1172\/jci.insight.147096","article-title":"Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions","volume":"6","author":"Gutkind","year":"2021","journal-title":"JCI Insight"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.ejca.2010.04.028","article-title":"Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib","volume":"46","author":"Guttman-Yassky","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2214\/AJR.21.26927","article-title":"Cancer risk in nodules detected at follow-up lung cancer screening CT","volume":"218","author":"Hammer","year":"2022","journal-title":"AJR Am. J. Roentgenol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3233\/blc-200423","article-title":"Efficacy of EGFR inhibitors and NSAIDs against basal bladder cancers in a rat model: Daily vs. Weekly dosing, combining EGFR inhibitors with naproxen, and effects on RNA expression","volume":"7","author":"Lubet","year":"2021","journal-title":"Bladder Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1158\/1940-6207.CAPR-12-0322","article-title":"Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis","volume":"6","author":"Lubet","year":"2013","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41598-021-04229-0","article-title":"Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs","volume":"12","author":"Maeda","year":"2022","journal-title":"Sci. Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1038\/s41467-021-24994-w","article-title":"Detection and characterization of lung cancer using cell-free DNA fragmentomes","volume":"12","author":"Mathios","year":"2021","journal-title":"Nat. Commun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/1940-6207.CAPR-08-0042","article-title":"Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial","volume":"1","author":"Meyskens","year":"2008","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/cncr.22088","article-title":"A phase I\/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer","volume":"107","author":"Milton","year":"2006","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1158\/1940-6207.CAPR-19-0339","article-title":"Combination of erlotinib and naproxen employing pulsatile or intermittent dosing profoundly inhibits urinary bladder cancers","volume":"13","author":"Mohammed","year":"2020","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1158\/1078-0432.CCR-18-3502","article-title":"Phase I study of intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases","volume":"25","author":"Morikawa","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/CAD.0b013e32836100d7","article-title":"Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: Brief report","volume":"24","author":"Padda","year":"2013","journal-title":"Anticancer Drugs"},{"key":"B36","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/sj.bjc.6604941","article-title":"Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients","volume":"100","author":"Park","year":"2009","journal-title":"Br. J. Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"33290","DOI":"10.18632\/oncotarget.5396","article-title":"Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma","volume":"6","author":"Rao","year":"2015","journal-title":"Oncotarget"},{"key":"B40","first-page":"2562","article-title":"Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet","volume":"50","author":"Reddy","year":"1990","journal-title":"Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.18.00440","article-title":"Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: Long-term follow-up of the BIG 1-98 trial","volume":"37","author":"Ruhstaller","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1158\/1940-6207.CAPR-13-0215","article-title":"Chemoprevention of head and neck cancer with celecoxib and erlotinib: Results of a phase ib and pharmacokinetic study","volume":"7","author":"Saba","year":"2014","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/jnci\/djx186","article-title":"Met receptor tyrosine kinase and chemoprevention of oral cancer","volume":"110","author":"Saintigny","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"B44","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1001\/jamaoncol.2017.5431","article-title":"Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis: Secondary analysis of a randomized clinical trial","volume":"4","author":"Samadder","year":"2018","journal-title":"JAMA Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2016.2522","article-title":"Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: A randomized clinical trial","volume":"315","author":"Samadder","year":"2016","journal-title":"JAMA"},{"key":"B46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5860","DOI":"10.1158\/1078-0432.CCR-20-2276","article-title":"Phase Ib study of chemoprevention with green tea polyphenon E and erlotinib in patients with advanced premalignant lesions (APL) of the head and neck","volume":"26","author":"Shin","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S1470-2045(14)70227-X","article-title":"Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): An open-label, randomised phase 3 trial","volume":"15","author":"Taieb","year":"2014","journal-title":"Lancet Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1056\/NEJMoa1211776","article-title":"Selection criteria for lung-cancer screening","volume":"368","author":"Tammemagi","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1158\/1940-6207.CAPR-20-0262","article-title":"Optimization of erlotinib plus sulindac dosing regimens for intestinal cancer prevention in an APC-mutant model of familial adenomatous polyposis (FAP)","volume":"14","author":"Ulusan","year":"2021","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-011-1621-0","article-title":"Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy\/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40)","volume":"132","author":"von Minckwitz","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"B53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jamaoncol.2015.4364","article-title":"Erlotinib and the risk of oral cancer: The erlotinib prevention of oral cancer (EPOC) randomized clinical trial","volume":"2","author":"William","year":"2016","journal-title":"JAMA Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial","volume":"13","author":"Yang","year":"2012","journal-title":"Lancet Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"72447","DOI":"10.18632\/oncotarget.19785","article-title":"Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2023.1170444\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T08:55:57Z","timestamp":1682326557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2023.1170444\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":55,"alternative-id":["10.3389\/fcell.2023.1170444"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2023.1170444","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"article-number":"1170444"}}